PT  - JOURNAL ARTICLE
AU  - Schuster, Nathaniel M.
AU  - Wallace, Mark S.
AU  - Marcotte, Thomas D.
AU  - Buse, Dawn C.
AU  - Lee, Euyhyun
AU  - Liu, Lin
AU  - Sexton, Michelle
TI  - Vaporized Cannabis versus Placebo for Acute Migraine: A Randomized Controlled Trial
AID  - 10.1101/2024.02.16.24302843
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.02.16.24302843
4099  - http://medrxiv.org/content/early/2024/02/18/2024.02.16.24302843.short
4100  - http://medrxiv.org/content/early/2024/02/18/2024.02.16.24302843.full
AB  - Background Preclinical and retrospective studies suggest cannabinoids may be effective in migraine treatment. However, there have been no randomized clinical trials examining the efficacy of cannabinoids for acute migraine.Methods In this randomized, double-blind, placebo-controlled, crossover trial, adults with migraine treated up to 4 separate migraine attacks, 1 each with vaporized 1) 6% Δ9-tetrahydrocannabinol (THC-dominant); 2) 11% cannabidiol (CBD-dominant); 3) 6% THC+11% CBD; and 4) placebo cannabis flower in a randomized order. Washout period between treated attack was ≥1 week. The primary endpoint was pain relief and secondary endpoints were pain freedom and most bothersome symptom (MBS) freedom, all assessed at 2 hours post-vaporization.Results Ninety-two participants were enrolled and randomized, and 247 migraine attacks were treated. THC+CBD was superior to placebo at achieving pain relief (67.2% vs 46.6%, Odds Ratio [95% Confidence Interval] 2.85 [1.22, 6.65], p=0.016), pain freedom (34.5% vs. 15.5%, 3.30 [1.24, 8.80], p=0.017) and MBS freedom (60.3% vs. 34.5%, 3.32 [1.45, 7.64], p=0.005) at 2 hours, as well as sustained pain freedom at 24 hours and sustained MBS freedom at 24 and 48 hours. THC-dominant was superior to placebo for pain relief (68.9% vs. 46.6%, 3.14 [1.35, 7.30], p=0.008) but not pain freedom or MBS freedom at 2 hours. CBD-dominant was not superior to placebo for pain relief, pain freedom or MBS freedom at 2 hours. There were no serious adverse events.Conclusions Acute migraine treatment with 6% THC+11% CBD was superior to placebo at 2 hours post-treatment with sustained benefits at 24 and 48 hours.Trial Registration Number NCT04360044Disclosures NMS has received research funding from Migraine Research Foundation, Novaremed, UCSD Academic Senate, UCSD Department of Anesthesiology RAG, and NIH CTSA Grant UL1TR000100 and has consulted for Eli Lilly & Co., Averitas, Syneos, Schedule 1 Therapeutics, Vectura Fertin, and ShiraTronics. He serves on the editorial board of Pain Medicine (Oxford University Press). DCB has been a consultant for Abbvie, Amgen, Biohaven, Lilly, Lundbeck, Teva, Theranica. She has received grant support from the US Food and Drug Association and National Headache Foundation. She is an editor for Current Pain and Headache Reports. MSW, TM, EL, LL and MS have no disclosures to report.Competing Interest StatementNMS has received research funding from Migraine Research Foundation, Novaremed, UCSD Academic Senate, UCSD Department of Anesthesiology RAG, and NIH CTSA Grant UL1TR000100 and has consulted for Eli Lilly & Co., Averitas, Syneos, Schedule 1 Therapeutics, Vectura Fertin, and ShiraTronics. He serves on the editorial board of Pain Medicine (Oxford University Press). DCB has been a consultant for Abbvie, Amgen, Biohaven, Lilly, Lundbeck, Teva, Theranica. She has received grant support from the US Food and Drug Association and National Headache Foundation. She is an editor for Current Pain and Headache Reports. MSW, TM, EL, LL and MS have no disclosures to report.Clinical TrialNCT04360044Funding StatementThis study was sponsored by the Migraine Research Foundation, now administered by Hartford HealthCare. The project described was partially supported by the UCSD Academic Senate and the National Institutes of Health, Grant UL1TR001442. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Study drug was provided by the National Institute on Drug Abuse Drug Supply Program. The authors thank the National Institute on Drug Abuse Drug Supply Program and the National Center for Natural Products Research at the University of Mississippi School of Pharmacy. Vaporizers were donated by Storz & Bickel GmbH & Co. KG, which did not provide any financial support of this study and was not involved in the design or conduct of the study or manuscript preparation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of California, San Diego Institutional Review Board (IRB #181944)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors